Zenosense, Inc. (ZENO) Issues Update on MRSA and Lung Cancer Zenosense, Inc. (ZENO) Issues Update on MRSA and Lung Cancer Device Development
Today before the opening bell, Zenosense reported on the status of development operations for its MRSA and lung cancer detection devices. Development efforts have been moving forward as planned. In its news release, Zenosense disclosed the following summarized recent achievements:
MRSA/SA
• A new sensor has been defined for manufacturing. It includes a new MRSA/SA VOC (Volatile Organic Compound) biomarker micro-separator technology.
• For this new technology, tests have been initiated to measure and contrast cultures of MRSA and SA.
• Electronics design for a microbiology lab device is complete, and industrial design for the device is in process.
• The electronics and new sensor are expected to be integrated in the coming weeks to produce the first prototype for laboratory detection of MRSA/SA in cultures.
Lung Cancer
• First tests using a LC VOC biomarker selected from existing hospital research data have been carried out.
• Good sensitivity to this VOC biomarker using the current sensor has been obtained, the VOC biomarker typically being expressed by LC patients at levels well within the capability of the sensor.
• Further tests will be carried out with the intent to resolve issues with cross-sensitivity with other VOC biomarkers and other ambient compounds.
• A review of literature and current research is in hand with alternative VOC biomarkers identified.
• A device for clinical tests with lung cancer patients has been designed, including electronics and a VOC capturing system. It is intended for this device to meet hospital clinical procedure requirements.
With its respected partner Sgenia Group, Zenosense seeks to develop effective medical devices targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. It intends to market and sell these products to hospitals and primary healthcare facilities. Intended for the timely detection of Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA) and lung cancer, these devices incorporate an advanced electronic nose technology to identify VOC signatures given by patients with this infection/illness.
For more information, visit: www.zenosense.net
Please see disclaimer on the QualityStocks website: https://Disclaimer.QualityStocks.com